SCHEMBL17799733

SCHEMBL17799733

O=C(N[C@H]1CC[C@H]1c1ccc(F)cc1F)c1ccccc1Cl

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HCRTR1 O43613 3/20 0.50
▸ HCRTR2 O43614 1/20 0.50
▸ HPGD P15428 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.44
▸ MC1R Q01726 1/20 0.43
▸ P2RX7 Q99572 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ TAS1R3 Q7RTX0 3/20 0.41
▸ TAS1R1 Q7RTX1 3/20 0.41
▸ TAS1R2 Q8TE23 3/20 0.41
▸ IDO1 P14902 1/20 0.41
▸ HSD11B1 P28845 1/20 0.40
▸ F10 P00742 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17799692 0.89 HCRTR1 (0.49) HCRTR1HCRTR2ALDH1A1LMNAGAA
SCHEMBL17799707 0.86 SIGMAR1 (0.42) HCRTR1HCRTR2HPGDMC1RKMT2A
SCHEMBL17799656 0.86 HCRTR1 (0.50) HCRTR1HCRTR2ALDH1A1MC1RKMT2A
SCHEMBL17799748 0.86 NPC1 (0.44) HCRTR1HCRTR2HPGDALDH1A1MC1R
SCHEMBL17799672 0.86 GAA (0.56) HCRTR1ALDH1A1LMNAGAAPKM
SCHEMBL17799632 0.84 EGFR (0.46) HCRTR1HCRTR2HPGDMC1RKMT2A
SCHEMBL17799693 0.84 TAS1R3 (0.47) HCRTR1HCRTR2MC1RLMNAGAA
SCHEMBL17799713 0.83 PPIA (0.41) HCRTR1HCRTR2HPGDMC1RTAS1R3
SCHEMBL17799746 0.82 MC1R (0.45) HCRTR1HCRTR2MC1RP2RX7LMNA
SCHEMBL17799743 0.81 SLC6A12 (0.47) HCRTR1HCRTR2HPGDALDH1A1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50724-E1 4-membered ring carboxamides used as nematicides SYNGENTA CROP PROTECTION AG (CH) 2026-01-06 — — US disclosed
EP-3019476-B1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-01-17 — — EP disclosed
US-9867371-B2 4-membered ring carboxamides used as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2018-01-16 — — US disclosed
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160157485-A1 4-MEMBERED RING CARBOXAMIDES USED AS NEMATICIDES TUBA3C, DDT, CYCS HCRTR1 57/4885HCRTR2 74/4885HPGD 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback